FDA Extends Comment Period for Public Meeting on Abuse-Deterrent Opioid Drug Products Evaluation

Summary

The Food and Drug Administration (FDA) is extending the comment period for a public meeting on evaluating the abuse-deterrent properties of opioid drug products, originally announced in the Federal Register on October 6, 2016. Interested persons now have additional time to submit comments on the approach to testing and standardized testing methodologies.